431 related articles for article (PubMed ID: 24842480)
1. Pathogenesis of systemic inflammatory diseases in childhood: "Lessons from clinical trials of anti-cytokine monoclonal antibodies for Kawasaki disease, systemic onset juvenile idiopathic arthritis, and cryopyrin-associated periodic fever syndrome".
Yokota S; Kikuchi M; Nozawa T; Kanetaka T; Sato T; Yamazaki K; Sakurai N; Hara R; Mori M
Mod Rheumatol; 2015 Jan; 25(1):1-10. PubMed ID: 24842480
[TBL] [Abstract][Full Text] [Related]
2. Unveiling the Efficacy, Safety, and Tolerability of Anti-Interleukin-1 Treatment in Monogenic and Multifactorial Autoinflammatory Diseases.
Bettiol A; Lopalco G; Emmi G; Cantarini L; Urban ML; Vitale A; Denora N; Lopalco A; Cutrignelli A; Lopedota A; Venerito V; Fornaro M; Vannacci A; Rigante D; Cimaz R; Iannone F
Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 30999610
[TBL] [Abstract][Full Text] [Related]
3. Canakinumab: a human anti-IL-1β monoclonal antibody for the treatment of cryopyrin-associated periodic syndromes.
Church LD; McDermott MF
Expert Rev Clin Immunol; 2010 Nov; 6(6):831-41. PubMed ID: 20979548
[TBL] [Abstract][Full Text] [Related]
4. [Canakinumab: a promising treatment in rheumatology].
Fabreguet I; So A
Rev Med Suisse; 2012 Jan; 8(323):57-60. PubMed ID: 22303742
[TBL] [Abstract][Full Text] [Related]
5. Canakinumab in pediatric rheumatic diseases.
Wulffraat NM; Woo P
Expert Opin Biol Ther; 2013 Apr; 13(4):615-22. PubMed ID: 23451862
[TBL] [Abstract][Full Text] [Related]
6. Tocilizumab: molecular intervention therapy in children with systemic juvenile idiopathic arthritis.
Yokota S; Kishimoto T
Expert Rev Clin Immunol; 2010 Sep; 6(5):735-43. PubMed ID: 20828281
[TBL] [Abstract][Full Text] [Related]
7. Canakinumab for the treatment of active systemic juvenile idiopathic arthritis.
Orrock JE; Ilowite NT
Expert Rev Clin Pharmacol; 2016 Aug; 9(8):1015-24. PubMed ID: 27367267
[TBL] [Abstract][Full Text] [Related]
8. A safety evaluation of canakinumab for the treatment of systemic onset juvenile idiopathic arthritis.
Wulffraat NM
Expert Opin Drug Saf; 2015; 14(12):1961-7. PubMed ID: 26568054
[TBL] [Abstract][Full Text] [Related]
9. Advances in the pathogenesis and treatment of systemic juvenile idiopathic arthritis.
Correll CK; Binstadt BA
Pediatr Res; 2014 Jan; 75(1-2):176-83. PubMed ID: 24213625
[TBL] [Abstract][Full Text] [Related]
10. Canakinumab.
Dhimolea E
MAbs; 2010; 2(1):3-13. PubMed ID: 20065636
[TBL] [Abstract][Full Text] [Related]
11. Tocilizumab for the treatment of systemic juvenile idiopathic arthritis.
Herlin T
Expert Rev Clin Immunol; 2012 Aug; 8(6):517-25. PubMed ID: 22992145
[TBL] [Abstract][Full Text] [Related]
12. Proinflammatory Cytokine Environments Can Drive Interleukin-17 Overexpression by γ/δ T Cells in Systemic Juvenile Idiopathic Arthritis.
Kessel C; Lippitz K; Weinhage T; Hinze C; Wittkowski H; Holzinger D; Fall N; Grom AA; Gruen N; Foell D
Arthritis Rheumatol; 2017 Jul; 69(7):1480-1494. PubMed ID: 28296284
[TBL] [Abstract][Full Text] [Related]
13. Systemic juvenile idiopathic arthritis-like syndrome in mice following stimulation of the immune system with Freund's complete adjuvant: regulation by interferon-γ.
Avau A; Mitera T; Put S; Put K; Brisse E; Filtjens J; Uyttenhove C; Van Snick J; Liston A; Leclercq G; Billiau AD; Wouters CH; Matthys P
Arthritis Rheumatol; 2014 May; 66(5):1340-51. PubMed ID: 24470407
[TBL] [Abstract][Full Text] [Related]
14. Systemic Juvenile Idiopathic Arthritis: Diagnosis and Management.
Kumar S
Indian J Pediatr; 2016 Apr; 83(4):322-7. PubMed ID: 26916892
[TBL] [Abstract][Full Text] [Related]
15. [Interleukin-6 as a pathogenic factor of systemic-onset juvenile idiopathic arthritis].
Yokota S
Nihon Rinsho Meneki Gakkai Kaishi; 2008 Apr; 31(2):99-103. PubMed ID: 18446012
[TBL] [Abstract][Full Text] [Related]
16. [Biologic response modifiers for juvenile idiopathic arthritis].
Yokota S
Nihon Rinsho; 2007 Jul; 65(7):1331-5. PubMed ID: 17642252
[TBL] [Abstract][Full Text] [Related]
17. Clinical study of tocilizumab in children with systemic-onset juvenile idiopathic arthritis.
Yokota S; Miyamae T; Imagawa T; Katakura S; Kurosawa R; Mori M
Clin Rev Allergy Immunol; 2005 Jun; 28(3):231-8. PubMed ID: 16129907
[TBL] [Abstract][Full Text] [Related]
18. Complications of systemic juvenile idiopathic arthritis: risk factors and management recommendations.
Woerner A; von Scheven-Gête A; Cimaz R; Hofer M
Expert Rev Clin Immunol; 2015 May; 11(5):575-88. PubMed ID: 25843554
[TBL] [Abstract][Full Text] [Related]
19. The pathogenesis of oligoarticular/polyarticular vs systemic juvenile idiopathic arthritis.
Lin YT; Wang CT; Gershwin ME; Chiang BL
Autoimmun Rev; 2011 Jun; 10(8):482-9. PubMed ID: 21320644
[TBL] [Abstract][Full Text] [Related]
20. [An approach to the patients with cryopyrin-associated periodic syndrome (CAPS) : a new biologic response modifier, canakinumab].
Yokota S; Kikuchi M; Nozawa T; Kizawa T; Kanetaka T; Miyamae T; Mori MA; Nishikomori R; Takata H; Heike T; Hara T; Imagawa T
Nihon Rinsho Meneki Gakkai Kaishi; 2012; 35(1):23-9. PubMed ID: 22374439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
